SBMFF Quote, Financials, Valuation and Earnings

Pharmaron Beijing has a net margin of -- compared to Sino Biopharmaceutical's net margin of --. Sino Biopharmaceutical's return on equity of 10.53% beat Pharmaron Beijing's return on equity of --.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharmaron Beijing has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical has higher upside potential than Pharmaron Beijing, analysts believe Sino Biopharmaceutical is more attractive than Pharmaron Beijing.

Sino Biopharmaceutical has a beta of 0.538, which suggesting that the stock is 46.165% less volatile than S&P 500. In comparison Pharmaron Beijing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 2.49%. Pharmaron Beijing offers a yield of 3.64% to investors and pays a quarterly dividend of $0.03 per share. Sino Biopharmaceutical pays 27.13% of its earnings as a dividend. Pharmaron Beijing pays out -- of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Pharmaron Beijing quarterly revenues of --. Sino Biopharmaceutical's net income of -- is lower than Pharmaron Beijing's net income of --. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 24.26x while Pharmaron Beijing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 1.97x versus 1.44x for Pharmaron Beijing. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to Sino Biopharmaceutical's net margin of -137.21%. Sino Biopharmaceutical's return on equity of 10.53% beat Prenetics Global's return on equity of -23.16%.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $9.00 which suggests that it could grow by 59.43%. Given that Prenetics Global has higher upside potential than Sino Biopharmaceutical, analysts believe Prenetics Global is more attractive than Sino Biopharmaceutical.

Sino Biopharmaceutical has a beta of 0.538, which suggesting that the stock is 46.165% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 2.49%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays 27.13% of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Sino Biopharmaceutical's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 24.26x while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 1.97x versus 2.72x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to Sino Biopharmaceutical's net margin of --. Sino Biopharmaceutical's return on equity of 10.53% beat Regencell Bioscience Holdings's return on equity of --.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical has higher upside potential than Regencell Bioscience Holdings, analysts believe Sino Biopharmaceutical is more attractive than Regencell Bioscience Holdings.

Sino Biopharmaceutical has a beta of 0.538, which suggesting that the stock is 46.165% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 2.49%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays 27.13% of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Sino Biopharmaceutical's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 24.26x while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 1.97x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Uni-Bio Science Group has a net margin of -- compared to Sino Biopharmaceutical's net margin of --. Sino Biopharmaceutical's return on equity of 10.53% beat Uni-Bio Science Group's return on equity of --.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical has higher upside potential than Uni-Bio Science Group, analysts believe Sino Biopharmaceutical is more attractive than Uni-Bio Science Group.

Sino Biopharmaceutical has a beta of 0.538, which suggesting that the stock is 46.165% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 2.49%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays 27.13% of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. Sino Biopharmaceutical's net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 24.26x while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 1.97x versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.